, Volume 51, Issue 2, pp 83–87 | Cite as

Cerebrospinal Fluid Levels of Interleukin-17 and Interleukin-34 in Patients with Neuro-Behcet’s Syndrome

  • M. N. ÖgünEmail author
  • Ş. Karabörk
  • M. Önerli
  • Ş. A. Türkoğlu
  • S. Yildiz

Behcet’s disease (BD) is a rather rare chronic multisystemic vasculitic disease. Clear neurological involvement is observed in up to 49% of patients with BD. Cytokines play a pivotal role in the pathogenesis of BD. Data on the cerebrospinal fluid (CSF) levels of cytokines in patients with Neuro-Behcet’s disease (NBD) are limited. We measured the CSF levels of Interleukin (IL)-17A, IL-17F, and IL-34 in 7 patients with NBD (median age of 38 years). Eleven control subjects were of a median age of 42 years. There was no significant difference in the male-to-female ratio and age between the NBD and control groups (P > 0.05). There was also no significant difference in biochemical values of CSF between NBD patients and control subjects. The CSF levels of IL-17 was significantly higher in patients with active NBD compared to the control (P < 0.05), whereas the CSF levels of IL-34 showed no difference compared to the control group (P > 0.05). This is the first study investigating the CSF levels of IL-34 in patients with NBD. Further studies with a larger sample size are required to confirm the role and values of the IL-34 levels in NBD.


neuro-Behcet’s syndrome cerebrospinal fluid cytokines interleukins IL-17 IL-34 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. Ciliz, B. Sakman, E. Fettahoǧlu, and E. Yuksel, “Nöro-Behçet hastalıǧında kranyal MRG bulguları,” Tanısal ve Girisimsel Radyoloji , 7, 452–459 (2001).Google Scholar
  2. 2.
    U. Uygunoğlu and A. Siva, “Behçet’s syndrome and nervous system involvement,” Curr. Neurol. Neurosci. Rep., 18, No. 7, 35 (2018).CrossRefPubMedGoogle Scholar
  3. 3.
    M. Z. Al Kawi, S. Bohlega, and M. Banna, “MRI findings in neuro-Behcet’s disease,” Neurology, 41, No. 3, 405–408 (1991).CrossRefPubMedGoogle Scholar
  4. 4.
    P. Serdaroğlu, “Behçet’s disease and the nervous system,” J. Neurol., 245, No. 4, 197–205 (1998).CrossRefPubMedGoogle Scholar
  5. 5.
    A. B. Haghighi, R. Pourmand, and A.-R. Nikseresht, “Neuro-Behçet disease: a review,” Neurologist, 11, No. 2, 80–89 (2005).CrossRefGoogle Scholar
  6. 6.
    U. Gangishetti, J. C. Howell, A. Kollhoff, and W. Hu, CSF Cytokine Profiles Uniquely Identify Different Neurodegenerative Disorders (P4. 175), AAN Enterprises (2018).Google Scholar
  7. 7.
    M. D. Turner, B. Nedjai, T. Hurst, and D. J. Pennington, “Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease,” Biochim. Biophys. Acta, 1843, No. 11, 2563–2582 (2014).CrossRefPubMedGoogle Scholar
  8. 8.
    E. Kugelberg, “Neuroimmunology: IL-17A mediates a path to autism,” Nat. Rev. Immunol., 16, No. 4, 205 (2016).CrossRefPubMedGoogle Scholar
  9. 9.
    P. Miossec, “Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice,” RMD Open, 3, No. 1, e000284 (2017).Google Scholar
  10. 10.
    M. Baghdadi, Y. Umeyama, N. Hama, et al., “Interleukin-34, a comprehensive review,” J. Leukoc. Biol., 104, No. 5, 931–951 (2018).CrossRefPubMedGoogle Scholar
  11. 11.
    M. Portelli and P. N. Papageorgiou, “An update on idiopathic intracranial hypertension,” Acta Neurochir. (Wien), 159, No. 3, 491–499 (2017).CrossRefGoogle Scholar
  12. 12.
    D. I. Friedman, “The pseudotumor cerebri syndrome,” Neurol. Clin., 32, No. 2, 363–396 (2014).CrossRefPubMedGoogle Scholar
  13. 13.
    [No authors listed], “Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease,” Lancet, 335, No. 8697, 1078–1080 (1990).Google Scholar
  14. 14.
    D. I. Friedman, G. T. Liu, and K. B. Digre, “Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children,” Neurology, 81, No. 13, 1159–1165 (2013).Google Scholar
  15. 15.
    C. C. Zouboulis and T. May, “Pathogenesis of Adamantiades-Behçet’s disease,” Med. Microbiol. Immunol., 192, No. 3,149–155 (2003).CrossRefPubMedGoogle Scholar
  16. 16.
    K. Hamzaoui, E. Bouali, and A. Hamzaoui, “Interleukin-33 and Behçet disease: another cytokine among others,” Hum. Immunol., 76, No. 5, 301–306 (2015).CrossRefPubMedGoogle Scholar
  17. 17.
    K. Hamzaoui, W. Kaabachi, B. Fazaa, et al., “Serum IL-33 levels and skin mRNA expression in Behçet’s disease,” Clin. Exp. Rheumatol., 31, No. 3, Suppl. 77, 6–14 (2013).Google Scholar
  18. 18.
    A. Sadeghi, F. Davatchi, F. Shahram, et al., “Serum profiles of cytokines in Behcet’s disease,” J. Clin. Med., 6, No. 5, 49 (2017).CrossRefPubMedCentralGoogle Scholar
  19. 19.
    M. Belghith, K. Bahrini, M. Kchaou, et al., “Cerebrospinal fluid IL-10 as an early stage discriminative marker between multiple sclerosis and neuro-Behçet disease,” Cytokine, 108, 160–167 (2018).CrossRefPubMedGoogle Scholar
  20. 20.
    A. B. Haghighi, H. Ittehadi, A. Nikseresht, et al., “CSF levels of cytokines in neuro-Behçet’s disease,” Clin. Neurol. Neurosurg., 111, No. 6, 507–510 (2009).CrossRefGoogle Scholar
  21. 21.
    S. Na, M. Park, S. Park, and E. Lee, “Up-regulation of Th17 and related cytokines in Behçet’s disease corresponding to disease activity,” Clin. Exp. Rheumatol., 31, No. 3, Suppl 77, 32–40 (2013).Google Scholar
  22. 22.
    D. S. Al-Zifzaf, A. N. Mokbel, and D. M. Abdelaziz, “Interleukin-17 in Behçet’s disease: relation with clinical picture and disease activity,” Egypt. Rheumatol. Rehabil., 42, No. 1, 34 (2015).CrossRefGoogle Scholar
  23. 23.
    Y. Nanke, T. Yago, and S. Kotake, “The role of Th17 cells in the pathogenesis of Behcet’s disease,” J. Clin. Med., 6, No. 7, 74 (2017).CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • M. N. Ögün
    • 1
    Email author
  • Ş. Karabörk
    • 2
  • M. Önerli
    • 1
  • Ş. A. Türkoğlu
    • 1
  • S. Yildiz
    • 1
  1. 1.Department of NeurologyMedical Faculty, Bolu Abant Izzet Baysal UniversityBoluTurkey
  2. 2.Department of Microbiology and ImmunolgyMedical Faculty, Bolu Abant Izzet Baysal UniversityBoluTurkey

Personalised recommendations